Direct answer
Myo-inositol studies report some insulin-related marker changes, but overall PCOS evidence is limited and inconclusive, with certainty varying by comparator and outcome. The 2023 guideline permits preference-based consideration with limited clinical benefits, endorses no specific preparation or dose, and treats infertility use as experimental. A tiny early-stopped ratio trial does not establish 40:1 as universally best. An earlier four-trial pregnancy subgroup suggested lower GDM risk with very-low certainty; the later 464-person pregnant-PCOS trial found no significant primary-complication or GDM reduction. Harms reporting is sparse, medicine-combination risks are not quantified here, and public funding or a no-conflict declaration does not clear every study’s financial relationships.
- Myo-inositol has been studied for PCOS, but the systematic review informing the 2023 guideline concluded that the evidence is limited and inconclusive. Possible effects on some metabolic measures do not establish reliable clinical or reproductive benefit (Fitz 2024).
- The 2023 PCOS guideline permits consideration according to individual preferences, while describing clinical benefits as limited. It cannot recommend a specific type, dose or combination. Its inositol recommendations have very-low certainty, and infertility use is experimental because benefits and risks remain uncertain (original recommendations 4.7 and 5.8).
- Metabolic findings depend on the comparison. Fitz found some insulin-related signals versus folate alone, but no clear difference versus metformin for several metabolic or reproductive outcomes. A nonsignificant contrast does not establish equivalence, reliable clinical benefit or a replacement for care (original outcome tables).
- The published EP2782559B1 patent names Lo.Li. Pharma as assignee and Vittorio Unfer as inventor; its claimed ratio range includes 40:1. That is a commercial interest, not proof of optimal efficacy or the legal status of every product. Unfer’s review discloses company ties, and the guideline endorses no specific blend (patent; review declarations; guideline).
- Harms reporting is sparse: Fitz’s review reports that 23 of 29 trials did not report adverse events. Research doses and unreported events do not establish long-term safety. These sources do not quantify a clinical interaction with glucose-lowering medicines; individual prescribing advice is needed (Discussion/safety synthesis; fertility safety recommendation).
- Evidence boundary: overall PCOS evidence is limited and inconclusive, with certainty varying by outcome and comparator. A dependable fertility/live-birth benefit or optimal blend is not established; the guideline treats infertility use as experimental (review; guideline).
Table of contents
- Evidence summary
- What myo-inositol is
- Preparations and combinations
- Proposed mechanisms
- Claims and evidence
- Benefits by claim
- Claims and limits
- Safety findings and gaps
- Medicines and evidence gaps
- Who should seek advice first
- Studied doses and food-use rules
- How mechanistic evidence is used
- Funding, conflicts and source roles
- Frequently asked questions
- Sources and funding notes
| Claim | Evidence | Source | Funding/conflict | Evidence boundary |
|---|---|---|---|---|
| Insulin-related markers in PCOS | Some comparisons favour treatment; results versus metformin often show no clear difference | Fitz; Unfer; Jethaliya | Fitz public support/outside interests; Unfer commercial ties; Jethaliya no specific grant/no COI declared | Overall limited/inconclusive; low or very-low certainty for several marker comparisons |
| Ovulation and menstrual frequency | Distinct outcomes; estimates are imprecise and clinical benefits limited | Fitz outcome tables; guideline | Review/guideline support and declared author relationships; constituent finances not fully traced | No dependable reproductive benefit; a null contrast is not equivalence |
| Inositol as PCOS infertility treatment | Guideline: experimental, with uncertain benefits and risks | recommendation 5.8 | Public/society support; panel commercial relationships declared | Very-low-certainty recommendation; limited ovulation, pregnancy and live-birth evidence |
| Androgen measures | Unfer total testosterone and androstenedione pools were not significant; Jethaliya found mixed hormone results | Unfer Results; Jethaliya original | Unfer/Orrù Lo.Li employees; Giordani paid consultant. Jethaliya no project grant/no COI declared | Biochemical changes are not proven hirsutism or fertility improvement |
| Gestational diabetes prevention | Earlier 4 g/day subgroup signal; later PCOS-pregnancy trial primary result and GDM comparison null | 2023 review; 2025 MYPP trial | Review reports no funding/COI; MYPP ZonMw support, purchased Gynov product and author outside ties | Different populations/formulations; routine prevention not established |
| 40:1 as an optimal blend | One tiny seven-arm open-label trial, terminated early, cannot establish universal optimality | Nordio original; patent; guideline | Pharcoterm prepared mixtures; separate trial funding/procurement unknown; authors declare no COI | 56 randomized/55 completed; eight allocated per arm, no placebo; no recommended blend |
| Supplement safety | Incomplete adverse-event reporting and uncertain fertility safety | review; guideline | Review support/relationships do not certify each safety study’s finances | No long-term, rare-harm or every-product safety determination |
What myo-inositol is
Myo-inositol is a naturally occurring sugar alcohol that the body synthesizes; the informal name “vitamin B8” does not make it a vitamin. It is also present in foods. The Open Heart narrative describes endogenous synthesis, but its estimates are not a personal supplement requirement (background review). Myo-inositol (MI or MYO) and D-chiro-inositol (DCI) are two of nine inositol stereoisomers discussed in metabolic/reproductive research; signalling hypotheses are distinct from clinical treatment effects (case-series background; clinical review). A May 2025 trade article called inositol a rising women’s-health trend using Spate metrics; that report does not establish current sales, why people use it or clinical efficacy (attributed trend report).
Preparations and combinations
Myo-inositol alone, combinations with D-chiro-inositol and combinations with folate are different preparations. A label, dosage form or shared ingredient does not establish equivalence to a studied protocol or superiority.
| Preparation | Composition | Studied protocol context | Evidence boundary |
|---|---|---|---|
| Myo-inositol alone | Single active inositol, sometimes with folate | Fitz identified MI protocols of 1–4 g/day, with varied controls and durations | No optimal dose or powder-versus-capsule equivalence established (trial synthesis; guideline) |
| Capsule/tablet presentation | Check actual MI amount and additional ingredients | Presentation is not a distinct proven clinical treatment | The guideline cannot recommend specific types or doses; packaging alone does not establish matched trial effects (recommendation 4.7.4) |
| MI:DCI 40:1 blend | Ratio by weight is distinct from total MI mass | Nordio tested 4 g/day TOTAL inositols, split into two doses; not 4 g “myo-equivalent” | Tiny open-label ratio study and a patent do not establish optimality (original Methods; patent; guideline) |
| MI:DCI 3.6:1 multi-ingredient blend | Ovosicare also included antioxidants, vitamins and minerals | Five uncontrolled IVF cases, with treatment and lifestyle co-interventions | Cannot isolate the ratio’s effect or compare efficacy with 40:1 (original cases) |
| MI plus folate | Some reviewed trials included 200–400 mcg/day folate | MYPP used 2 g MI plus 200 mcg folate twice daily against folate placebo | Folate co-administration does not prove PCOS/fertility benefit or equivalence to other blends (protocol review; original Methods) |
Proposed mechanisms
Inositol-containing signalling pathways provide a biological rationale for research into insulin sensitivity and ovarian function. The narrative reviews discuss physiology alongside cell/animal mechanisms; they do not directly show that a retail supplement restores a pathway in patients or that a particular ratio is clinically optimal (mechanistic narrative; ratio narrative). Human outcomes and the guideline appraisal remain the basis for clinical conclusions (clinical review; guideline).
Claims and evidence
The relevant clinical questions concern insulin-related markers, cycle/ovulation outcomes, fertility, pregnancy complications and particular blend ratios. These outcomes require separate evidence; “hormone balance” is not one defined clinical endpoint.
- PCOS metabolic markers: Fitz 2024 concluded that the overall evidence is limited and inconclusive. Some comparisons suggest potential metabolic effects, but these surrogate findings do not establish dependable clinical benefits.
- Ovulation and fertility: The 2023 PCOS guideline treats infertility use as experimental because benefits and risks are too uncertain for a recommendation. Its certainty rating is very low (⊕◯◯◯). A proven fertility benefit is not established.
- Insulin-related markers: older reviews and individual comparisons differ. Jethaliya’s mixed-control meta-analysis did not find significant fasting insulin, glucose or HOMA differences, with substantial heterogeneity. Fitz’s comparison-specific results include some marker signals versus folate alone, while the overall evidence remains limited/inconclusive. Neither finding proves all formulations effective or ineffective (original Results/limitations; outcome tables).
- Hormonal outcomes: changes in one blood measure do not establish general “hormone balance”, hirsutism improvement or fertility benefit. Unfer’s overall testosterone and androstenedione results were null; Jethaliya reported mixed measures with high heterogeneity. Unfer disclosed Lo.Li employee/paid-consultant ties; Jethaliya declared no specific project grant/no competing interests, which does not clear all constituent trials (Results/disclosures; original main paper).
The clinical evidence warrants a cautious, individualized discussion. Neither guideline inclusion nor a favorable surrogate marker establishes a proven PCOS treatment, fertility benefit or optimal commercial blend. (2024 guideline evidence review; 2023 PCOS guideline)
Benefits by claim
Insulin resistance and metabolic markers
Metabolic findings depend on population and control treatment. The 8-week HOMA/adiponectin experiment described by Formoso involved pregnant women with GDM; it is not a PCOS treatment trial, and that original constituent trial was not independently read here (pregnancy narrative). Unfer’s insulin/HOMA signals had substantial heterogeneity and company-linked authors. Jethaliya’s mixed-control pools were largely null for these markers. Fitz judged overall PCOS evidence limited and inconclusive (Results/disclosures; original review; comparison-specific synthesis).
Ovulation and menstrual regularity
Zhao’s network meta-analysis estimated improved menstrual frequency with MI+DCI versus metformin (OR 14.70; 95% CI 2.31–93.58). It combines direct and indirect evidence; the direct contrast came from one 64-person study. This very imprecise menstrual endpoint is not ovulation or live birth, and does not establish dependable clinical superiority. The review reports public/institutional support and no COI; constituent trial finances are separate (original Methods/Table 2). The guideline describes limited ovulation benefits and recommends no specific combination (recommendations).
Fertility and live birth
The 2023 guideline treats inositol for PCOS infertility as experimental because benefits and risks are too uncertain for a treatment recommendation. Ovulation, clinical pregnancy and live-birth evidence is limited, with a very-low-certainty recommendation and unknown safety/side effects in this context. This differs from the separate preference-based consideration of inositol for other PCOS goals (recommendations 4.7 and 5.8).
Gestational diabetes prevention
Factor/Corpuz reviewed six pregnancy trials with varied formulations. The 4 g/day subgroup consisted of four trials and 887 participants, with GDM RR 0.54 (95% CI 0.30–0.96), I² 78% and very-low certainty; 887 is not the total for all six trials (original Results/Table 1). MYPP later randomized 464 pregnant people with PCOS to 4 g/day MI plus folate or matched folate placebo. Its primary pregnancy-complication composite was 25.0% versus 26.8% (RR 0.93; 0.68–1.28), and GDM was 17.0% versus 15.8% (RR 1.07; 0.71–1.63). Neither contrast was significant. Adherence was low; routine prevention in this population was not established (original Methods/Results).
Androgen levels and hyperandrogenism
Biochemical androgen results are inconsistent and do not by themselves establish improvement in hirsutism. Unfer’s overall testosterone/androstenedione pools were null, while Jethaliya reported an androstenedione signal amid largely null other measures and high heterogeneity (original Results; original Results). Laganà’s article is expert opinion with Lo.Li employee authors; the selected opinion/declaration sections were read, rather than treating it as a new controlled trial (expert opinion). The guideline prefers metformin for hirsutism and central adiposity (recommendation 4.7.2).
Claims and limits
| Claim | Verdict | Evidence basis |
|---|---|---|
| Improves insulin resistance/HOMA-IR in PCOS | Possible effects in some comparisons; overall PCOS evidence limited/inconclusive | Fitz 2024; Jethaliya 2022 |
| Menstrual frequency | Imprecise combined direct/indirect network signal, not ovulation/live birth | One small direct MI+DCI versus metformin comparison; no specific blend endorsed (Table 2; guideline) |
| Improves live birth rates in PCOS infertility | Not established — explicitly “experimental therapy” per guideline | Teede 2023 |
| Androgen/hirsutism improvement | Mixed biochemical measures, uncertain clinical benefit | Unfer overall testosterone/androstenedione null; Jethaliya high-heterogeneity mixed measures (Results; Results) |
| GDM prevention | Routine prevention not established in MYPP pregnant-PCOS population | Earlier four-trial 4 g subgroup signal was very-low certainty; later primary composite/GDM null (subgroup review; MYPP) |
| 40:1 universally superior | Not established by tiny early-stopped open-label study | 56 randomized/55 completed in seven arms; patent does not prove efficacy; no recommended blend (original; patent; guideline) |
| “Fixes” PCOS on its own | A dependable clinical treatment benefit is not established | Preference-based consideration with limited clinical benefits differs from proven standalone therapy (recommendation 4.7.1) |
Safety findings and gaps
| Safety question | Reported context and limit | Source |
|---|---|---|
| Digestive symptoms | Narrative reports of GI effects, especially at high doses; no reliable universal frequency or severity estimate | selected safety narrative; incomplete trial harms reporting |
| High-dose tolerability claims | Narrative review cites 18 g/day; this does not establish a safe PCOS regimen | Open Heart review; Fitz 2024 |
| Long-term safety | Narrative review cites 4 g/day for 12 months; population and sparse harms reporting limit extrapolation | Open Heart review; Fitz 2024 |
| GI events versus metformin | Six-trial pool favoured fewer GI events; two low-bias studies did not show a clear difference | Comparison-specific result, not safety of taking both together (Results/sensitivity) |
| Glucose-lowering medicines | These sources do not quantify a clinically established hypoglycaemia interaction | MYPP excluded concurrent hypoglycaemic agents; review actual medicines with the prescriber (eligibility; review scope) |
| Overall safety and side-effect profile in PCOS trials | Guideline identifies uncertain safety for experimental fertility use; most reviewed trials did not report harms (2023 PCOS guideline; 2024 guideline evidence review) | Teede 2023 |
Fitz’s Discussion reports that 23 of 29 trials did not report adverse events; its total review included 30 unique trials. This is the review’s reported harms count, not a new reconstruction. Missing reports cannot establish absence of serious or long-term harms. The guideline separately describes safety and side effects as unknown for experimental infertility use (Discussion; recommendation 5.8.3).
Medicines and evidence gaps
| Drug/substance class | Mechanism of concern | Severity/guidance | Evidence status |
|---|---|---|---|
| Glucose-lowering medicines, including insulin/metformin/sulfonylureas | These sources do not quantify the effect of each concurrent combination | Review the regimen with the prescriber; monitor as individually advised | Mechanistic glucose effects are not proof of additive clinical hypoglycaemia; MYPP excluded concurrent hypoglycaemic agents (review scope; trial eligibility) |
| Fertility protocols | Reviewed studies used varied fertility co-interventions; combination use does not prove absence of interactions | Use only under fertility-specialist advice | Guideline infertility use remains experimental, with unknown safety (trial synthesis; recommendation 5.8) |
| Other prescribed medicines | The sources reviewed here do not quantify a risk for every medication combination | Ask a clinician/pharmacist to assess the actual medicines and product | This is an evidence boundary, not a systematic proof that every listed class lacks interaction studies |
Who should seek advice first
- People taking glucose-lowering medicines should discuss the exact product with their prescriber. These sources do not quantify a clinical hypoglycaemia interaction, and MYPP excluded concurrent hypoglycaemic therapy; its safety observations cannot answer that combination question (review scope; trial eligibility).
- Anyone treating infertility hoping for a guaranteed live-birth benefit should know the leading international guideline rates this use as experimental with unknown risk-benefit balance, not a proven treatment (Teede 2023).
- Pregnant people should discuss use with their treating clinician. The newer large PCOS pregnancy trial did not establish preventive benefit; smaller earlier studies and incomplete safety reporting do not justify self-directed prevention. (2025 JAMA trial; 2023 pregnancy meta-analysis)
- A patent or positive small study does not establish a best ratio. EP2782559B1 includes 40:1; Unfer’s review discloses company ties; Nordio’s ratio trial was tiny, open-label and stopped early. The guideline recommends no specific combination (patent; disclosures; original Methods/Results; guideline).
Studied doses and food-use rules
| Parameter | Value | Source |
|---|---|---|
| MI protocols in Fitz | 1–4 g/day, sometimes with folate; varied durations/controls | Observed protocols, not a personal dose or proof of form equivalence (trial review; no specific dose endorsement) |
| 40:1 protocol in Nordio | 4 g/day TOTAL MI+DCI, divided twice daily for three months | 56 randomized/55 completed; no best timing or ratio established (original Methods; guideline) |
| Short-term high-dose tolerability | Narrative review describes 18 g/day for 3 months; not established as a safe PCOS dose | Open Heart review; guideline safety limitations |
| Long-term tolerability | Narrative review describes 4 g/day for 12 months; long-term harms remain uncertain | Open Heart review; guideline safety limitations |
| Guideline dose/form position | Specific types, doses or combinations cannot currently be recommended | Recommendation 4.7.4 reflects inadequate-quality evidence, not proven equivalence or no possible effect (original recommendation) |
| US specified food use | 21 CFR 184.1370 permits specified nutrient-supplement food use under current good manufacturing practice | Identity/specification and special-diet/infant-formula conditions apply; not PCOS/drug approval or every supplement-dose clearance (FDA record; original rule) |
How mechanistic evidence is used
Clinical conclusions are based on human outcomes and guideline appraisal. Mechanistic reviews also contain cell and animal research, which is background rather than proof of clinical efficacy. Some clinical reviews have commercial conflicts, and publicly funded reviews do not make every underlying trial independent. These limitations remain part of the assessment. (2024 guideline evidence review; 2023 PCOS guideline; Open Heart review and disclosures; 2017 review and disclosures)
Funding, conflicts and source roles
Research funding at a glance
10 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Declared support / relationships | Role and remaining limits |
|---|---|---|
| Fitz 2024 guideline evidence review | NHMRC CREWHIRL 1171592; outside nutraceutical/institutional interests and other author roles declared | Public funding does not eliminate outside relationships or certify all constituent trials (original declarations) |
| 2023 international PCOS guideline | NHMRC APP 1171592; partner societies; MRFF translation support; several panel pharmaceutical relationships | Funding/managed interests are disclosed, rather than an all-evidence independence certificate (Funding/Disclosures) |
| Jethaliya 2022 | Author-uploaded original main: no specific project grant/no competing interests declared | 17 mixed-comparator trials with high heterogeneity; underlying study finances/procurement not all traced (original paper record) |
| Zhao 2021 network review | NSFC 81570765/Shengjing 345 Talent Project; no COI declared | Direct and indirect menstrual-frequency evidence; full underlying trial finances not traced (original) |
| Unfer 2017 | Unfer/Orrù Lo.Li employees; Giordani paid Lo.Li consultant for this meta-analysis | No specific public/not-for-profit grant does not erase commercial relationships; constituent procurement not fully traced (original declarations) |
| Nordio 2019 | Pharcoterm prepared blends; no COI declared; separate funding line not located | 56 randomized/55 completed, early-stopped open-label trial; purchase/donation/cash terms unknown (full original) |
| EP2782559B1 | Patent lists Lo.Li assignee/Unfer inventor and ratios including 40:1 | Current enforceability/royalties/ultimate ownership not verified; patent is not clinical proof (published record) |
| 2024 five-case IVF series | Authors report no financial support/no conflicts; Ovosicare compound used | Uncontrolled co-interventions; actual product purchase/donation terms unreported (original cases/declarations) |
| Open Heart 2022 narrative | DiNicolantonio AIDP scientific-affairs director; associated companies sell MI. O’Keefe owns a supplement company | Selected background/safety sections are narrative, not an independent clinical trial or every constituent original clearance (original disclosures) |
| 2023 GDM review / 2025 MYPP trial | Review: no funding/no COI. MYPP: ZonMw 848016013, Gynov SAS product PURCHASED, outside author pharmaceutical ties | Manufacturer reported no funding or research/writing role; purchase terms/amounts and full constituent finances not itemised (review declarations; trial disclosures) |
Frequently asked questions
Does myo-inositol actually help with PCOS?
Some comparisons suggest marker changes, but effects vary by comparator and certainty. Fitz calls the overall evidence limited/inconclusive. The guideline permits preference-based consideration with limited clinical benefits and cannot endorse a particular preparation or dose. That is not proof of a dependable PCOS treatment or equivalence to metformin (outcome synthesis; recommendations 4.7).
Will myo-inositol improve my chances of getting pregnant or having a live birth?
A dependable pregnancy or live-birth benefit is not established. The guideline treats PCOS infertility use as experimental, with uncertain benefits/risks and limited reproductive evidence. It also describes safety/side effects as unknown in that context (recommendations 5.8). An uncontrolled IVF case series cannot establish that a particular ratio caused live births (original cases).
What’s the difference between myo-inositol alone and the 40:1 blend?
MI alone and MI+DCI blends differ in ingredients and mass. Nordio tested 4 g/day total inositols across seven tiny groups; its early-stopped open-label result cannot identify a universally optimal ratio (original study). EP2782559B1 includes 40:1, but a patent is not proof of efficacy, all-product coverage or current enforceability. The guideline recommends no particular combination (patent; recommendation 4.7.4).
Is myo-inositol safe to take with metformin or other diabetes medication?
Comparing MI with metformin is different from testing their combined safety. Fitz’s GI pool favoured MI, but low-bias sensitivity showed no clear difference. These sources do not quantify clinical hypoglycaemia risk for each combination; MYPP excluded concurrent hypoglycaemic medicines. Discuss the exact regimen with the prescriber (GI synthesis; trial eligibility).
How much myo-inositol should I take?
Fitz identified MI protocols of 1–4 g/day, sometimes with folate; Nordio’s ratio experiment used 4 g/day total mixed inositols. These are different quantities and not personal recommendations. Historical high-dose tolerability reports do not establish a safe long-term regimen, and the guideline cannot recommend particular types, doses or combinations (protocol synthesis; original Methods; safety narrative; recommendation 4.7.4).
Is myo-inositol regulated or approved as a drug?
FDA’s ingredient record points to 21 CFR 184.1370. The rule concerns specified food uses under current good manufacturing practice and identity/specification conditions, including separate special-diet/infant-formula conditions. It is not approval of PCOS or infertility treatment or every retail supplement dose. The guideline notes that supplement quality/regulation may differ from medicines (FDA record; original food-use rule; recommendation 4.7.5).
Sources and funding notes
- Fitz 2024 inositol guideline evidence review — Thirty unique PCOS trials; comparison-specific certainty and overall limited/inconclusive evidence. NHMRC support and outside author/institutional relationships declared; not a complete constituent-trial financial certificate.
- Teede 2023 international PCOS guideline — Relevant Methods, recommendations 4.7/5.8 and complete article disclosures read. Public/society support and panel outside relationships; no specific inositol type/dose/combination endorsed.
- Flinders-hosted original Teede guideline PDF — Same guideline as the OUP/PMC record, not a separate replication or additional clinical trial.
- DiNicolantonio/O’Keefe 2022 Open Heart narrative — Selected physiology, PCOS/GDM, historical safety and declaration sections read. AIDP/supplement-company author relationships disclosed; not an optimal-dose or clinical-efficacy certificate.
- Formoso 2019 pregnancy review — Selected MYO pregnancy/GDM, safety and declarations read. Unfunded/no COI declared; constituent trial finances not fully traced. Its GDM trial account is not a PCOS treatment population.
- van der Wel 2025 MYPP randomized trial — Pregnant-PCOS primary composite and GDM contrasts null; ZonMw 848016013 support, purchased Gynov SAS supplements and outside author ties. Original main Methods/Results/declarations read; supplement protocol/SAP not read.
- Factor/Corpuz 2023 GDM prevention review — Six trials overall; four-trial 4 g/day subgroup 887 participants, very-low certainty. No review funding/COI declared; constituent finances separate.
- Unfer 2017 PCOS meta-analysis — Nine trials 496 participants; selected metabolic signals with high heterogeneity, overall testosterone/androstenedione null. Lo.Li employees and paid consultant disclosed.
- Jethaliya 2022 metabolic/endocrine meta-analysis — Seventeen mixed-comparator trials; largely null major marker pools, high heterogeneity and some prose/table reporting differences. Author-uploaded original main/declarations read; no project grant/no COI declared, constituent finances unknown.
- Zhao 2021 PCOS network meta-analysis — Direct plus indirect comparisons; menstrual-frequency signal is not ovulation/live birth. NSFC/Shengjing support, no COI declared; constituent financial terms not cleared.
- Nordio/Basciani/Camajani 2019 ratio-trial record and full original paper — Same 56-randomized/55-completer study; seven tiny open-label groups, early termination and no placebo. Pharcoterm prepared mixtures; no COI declared, separate funding/procurement terms unknown.
- Roseff/Montenegro 2020 narrative ratio review — Selected clinical/history/conclusion/declaration sections read; advocates 40:1 using small trials and nonclinical mechanisms. No COI declared; separate funding line not located. Not independent replication or a substitute for the newer guideline.
- 2024 Ovosicare five-case IVF series — 3.6:1 multi-ingredient preparation with co-interventions, no control. No financial support/COI declared; product procurement not itemised. Cannot isolate ratio efficacy.
- EP2782559B1 published patent — Lo.Li assignee/Unfer inventor; ratio claims include 40:1. Current enforceability, royalties and ultimate ownership not independently verified; patent is not clinical proof.
- Lete 2024 combination review — Original indexed abstract/first-page and funding/COI records read; full main paper not recovered. Sakura, Italy funding and no potential COI declared. Not used as proof of optimal ratio; ultimate funder backing/terms unknown.
- Direct guideline infertility recommendations 5.8 — Experimental use with limited reproductive evidence and unknown safety; this original guideline is the fertility-recommendation basis.
- Laganà 2024: Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future — Selected original expert-opinion/conclusion/declaration sections read. Unfunded article; Myers/Forte/Unfer Lo.Li employees. Not a new independent controlled trial.
- 2024 Serbian MI versus metformin study — 80 randomized/60 completers; MI+folate 8 months versus metformin 6 months, unequal attrition/duration. No external funding/no COI declared; procurement unknown. Does not establish equivalence or reliable fertility benefit.
- Open Heart 2022 mechanisms/trial-history review — Same narrative source already listed, not an additional trial or independent replication; author supplement-company ties and constituent-original limits apply.
- FDA inositol ingredient record and 21 CFR 184.1370 original rule — Specified food-use conditions, not PCOS/infertility drug approval or all-dose safety.
- NutraIngredients/Spate May 2025 report — Attributed commercial trend context. Underlying proprietary metrics/financial influence not independently reconstructed; no clinical-efficacy inference.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.